Payment overview · 2025
General Payments
$113.15
7 reported records · 4 companies
Healthcare provider profile · identity verified
Charles Lunn
Allopathic & Osteopathic Physicians|Family Medicine · OKLAHOMA CITY, OK · NPI 1477529535
Verified facts
What the public records show
CMS Open Payments records show Charles Lunn received $113.15 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 43.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.07 | 43.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.65 | 28.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.92 | 15.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.51 | 12.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $113.15 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.07 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.65 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.65 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
143 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 628 | 206 |
| Amlodipine Besylate | Amlodipine Besylate | 624 | 198 |
| Prednisone | Prednisone | 362 | 180 |
| Losartan Potassium | Losartan Potassium | 359 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 338 | 102 |
| Hydrochlorothiazide | Hydrochlorothiazide | 318 | 99 |
| Lisinopril | Lisinopril | 264 | 81 |
| Gabapentin | Gabapentin | 249 | 82 |
| Metformin Hcl | Metformin Hcl | 229 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 199 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 71 |
| Furosemide | Furosemide | 194 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 182 | 55 |
| Ibuprofen | Ibuprofen | 176 | 52 |
| Trazodone Hcl | Trazodone Hcl | 156 | 50 |
| Jardiance | Empagliflozin | 143 | 34 |
| Meloxicam | Meloxicam | 139 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 129 | 48 |
| Omeprazole | Omeprazole | 120 | 38 |
| Baclofen | Baclofen | 114 | 46 |
| Ozempic | Semaglutide | 113 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 41 |
| Sertraline Hcl | Sertraline Hcl | 112 | 37 |
| Eliquis | Apixaban | 106 | 24 |
| Morphine Sulfate Er | Morphine Sulfate | 101 | 13 |
| Glipizide | Glipizide | 94 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | 22 |
| Atenolol | Atenolol | 89 | 25 |
| Naproxen | Naproxen | 87 | 22 |
| Carvedilol | Carvedilol | 84 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 24 |
| Spironolactone | Spironolactone | 83 | 31 |
| Lorazepam | Lorazepam | 81 | 13 |
| Potassium Chloride | Potassium Chloride | 80 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 23 |
| Allopurinol | Allopurinol | 79 | 27 |
| Glipizide Er | Glipizide | 79 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 19 |
| Farxiga | Dapagliflozin Propanediol | 64 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 29 |
| Montelukast Sodium | Montelukast Sodium | 61 | 22 |
| Tramadol Hcl | Tramadol Hcl | 60 | 26 |
| Azithromycin | Azithromycin | 59 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 58 | 13 |
| Metformin Hcl Er | Metformin Hcl | 57 | 21 |
| Simvastatin | Simvastatin | 57 | 21 |
| Alprazolam | Alprazolam | 56 | 19 |
| Famotidine | Famotidine | 54 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 14 |
| Meclizine Hcl | Meclizine Hcl | 45 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 14 |
| Warfarin Sodium | Warfarin Sodium | 41 | 14 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 41 | 17 |
| Fluconazole | Fluconazole | 39 | 28 |
| Memantine Hcl | Memantine Hcl | 39 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 23 |
| Alendronate Sodium | Alendronate Sodium | 34 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | 12 |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | 14 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Diazepam | Diazepam | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Nitroglycerin | Nitroglycerin | 13 | 12 |
| Topiramate | Topiramate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Caplyta | Lumateperone Tosylate | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $113.15 · 7 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, MOUNJARO, OTEZLA, REPATHA, VRAYLAR, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error